eFinder

eFinder

Home › Investor Relations › Article

Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals

Cnbc · · 322 words · By Angelica Peebles
Investor Relations Pharmaceutical Competition Corporate Strategy
open_in_new Read the original article: https://www.cnbc.com/2026/05/06/novo-nordisk-ceo-mike-doustdar-ozempic-maker-loo…

psychologyDetected Techniques

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.
warning
Glittering Generalities 60% confidence
Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

fact_checkFact-Check Results

8 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

check_circle Corroborated 5
verified Verified By Reference 1
info Single Source 1
cancel Disputed 1
check_circle
“Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday.”
CORROBORATED
Multiple CNBC reports and an MSN link confirm that CEO Mike Doustdar stated in a CNBC interview that Novo Nordisk is looking for deals more than ever before.
menu_book
wikipedia NEUTRAL — Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novonesis (formerly Novozymes A/S). Novo Holdings A/S was established in 19…
https://en.wikipedia.org/wiki/Novo_Holdings_A/S
menu_book
wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk
menu_book
wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardio…
https://en.wikipedia.org/wiki/Semaglutide
+ 3 more evidence sources
verified
“Novo created the market for GLP-1 weight loss drugs with its weekly shots Ozempic and Wegovy.”
VERIFIED BY REFERENCE
Wikipedia and web results confirm Novo Nordisk's role in the GLP-1 market with semaglutide-based drugs Ozempic and Wegovy.
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
menu_book
wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk
menu_book
wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardio…
https://en.wikipedia.org/wiki/Semaglutide
+ 3 more evidence sources
check_circle
“Rival Eli Lilly has already overtaken Novo in market share for weekly GLP-1 shots”
CORROBORATED
Multiple web sources report that Eli Lilly has pulled ahead or is dominating the GLP-1 race, overtaking Novo Nordisk's initial dominance.
menu_book
wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
menu_book
wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk
+ 3 more evidence sources
info
“Novo has taken an early lead in the new category of GLP-1 pills for weight loss.”
SINGLE SOURCE
While sources mention Novo's success with semaglutide and the existence of a Wegovy pill, there is no specific evidence in the provided results confirming they have an 'early lead' in the pill category specifically over competitors.
travel_explore
web search NEUTRAL — Eli Lilly and Novo Nordisk whipsawed by Wall Street's ever-rising hopes for weight loss drugs. The drug makers' stock prices gyrate at the slightest whiff of bad news for GLP-1 medicines.
https://qz.com/eli-lilly-novo-nordisk-wall-street-expectatio…
travel_explore
web search NEUTRAL — Novo Nordisk has achieved tremendous success in the cardiometabolic treatment space, all thanks to its semaglutide medicines, Ozempic, Rybelsus and Wegovy, which are its primary top-line drivers.
https://finviz.com/news/288528/novo-nordisk-vs-viking-which-…
travel_explore
web search NEUTRAL — Novo Nordisk made insulin before GLP-1 drugs. Novo Nordisk is one of the world's largest producers of insulin, a vital medication for those with diabetes. Generally speaking, when you take insulin, yo…
https://finance.yahoo.com/news/1-reason-why-id-hold-18200024…
cancel
“He pointed to Novo's CagriSema, a drug candidate that targets GLP-1 and amylin, that Novo hopes will be approved at the end of this year”
DISPUTED
One source says the FDA could review the application 'this year', but another specific tracker states the NDA was filed in December 2025 and a decision is expected in 'late 2026', contradicting the 'end of this year' timeline.
travel_explore
web search NEUTRAL — Called CagriSema, this investigational weight-loss drug by Novo Nordisk combines semaglutide and cagrilintide.CagriSema is currently in phase 3 trials, and the FDA could review its application for app…
https://www.weightwatchers.com/us/blog/weight-loss/new-weigh…
travel_explore
web search NEUTRAL — The current range of weight-loss drugs on the market targets GLP-1 receptors. Seeking a new generation of weight-loss drugs, some companies are developing amylin analogs.
https://cen.acs.org/pharmaceuticals/amylin-weight-loss-drugs…
travel_explore
web search NEUTRAL — Novo Nordisk filed a New Drug Application (NDA) with the FDA in December 2025 based on the REDEFINE 1 trial showing 22.7% weight loss. An FDA decision is expected in late 2026. If approved, CagriSema …
https://remypeptides.com/research/obesity-drug-approval-trac…
check_circle
“an experimental amylin-targeting drug called zenagamtide that Novo has accelerated development of”
CORROBORATED
Multiple sources confirm the existence of zenagamtide (also known as amycretin) as an amylin-targeting drug developed by Novo Nordisk.
travel_explore
web search NEUTRAL — He pointed to Novo's CagriSema, a drug candidate that targets GLP-1 and amylin, that Novo hopes will be approved at the end of this year, and an experimental amylin-targeting drug called zenagamtide t…
https://www.msn.com/en-us/money/general/novo-nordisk-ceo-say…
travel_explore
web search NEUTRAL — Zenagamtide (formerly amycretin) is Novo Nordisk’s unimolecular GLP-1 and amylin receptor agonist — a single molecule targeting both pathways simultaneously.Novo Nordisk has also developed oral versio…
https://remypeptides.com/research/zenagamtide-amycretin-glp1…
travel_explore
web search NEUTRAL — Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending hopes of delivering the therapy in a single-chamber device.
https://www.fiercebiotech.com/biotech/novo-ceo-insists-no-ch…
check_circle
“the company said its Wegovy pill performed better than expected in the first quarter”
CORROBORATED
Multiple independent reports state that the oral version of Wegovy significantly exceeded expectations in the first quarter.
menu_book
wikipedia NEUTRAL — Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novonesis (formerly Novozymes A/S). Novo Holdings A/S was established in 19…
https://en.wikipedia.org/wiki/Novo_Holdings_A/S
menu_book
wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk
menu_book
wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardio…
https://en.wikipedia.org/wiki/Semaglutide
+ 3 more evidence sources
check_circle
“it raised its full-year profit guidance.”
CORROBORATED
Multiple sources confirm that Novo Nordisk raised its full-year profit guidance or adjusted earnings per share guidance.
travel_explore
web search NEUTRAL — Danish pharmaceutical company Novo Nordisk reported revenue in line with expectations for the first quarter. Operating profit was better than expected. Revenue rose 19.5 percent to DKK 78,087 million …
https://in.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1…
travel_explore
web search NEUTRAL — Novo Nordisk lowers full-year profit guidance as sales slow.The company reaffirmed its full-year revenue guidance ($61 billion to $64 billion) and raised its full-year adjusted earnings per share guid…
https://au.finance.yahoo.com/news/earnings-live-amd-supermic…
travel_explore
web search NEUTRAL — Weight-loss drug pioneer Novo Nordisk increased its profit projections for the year.To top it all off, Novo slightly increased its outlook for profit and sales this year as a whole.
https://finimize.com/content/winning-from-losing
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.